Rabies - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rabies - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Rabies - Pipeline Review, H2 2015', provides an overview of the Rabies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rabies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rabies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rabies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rabies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rabies
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rabies pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Rabies Overview 9
Therapeutics Development 10
Pipeline Products for Rabies - Overview 10
Pipeline Products for Rabies - Comparative Analysis 11
Rabies - Therapeutics under Development by Companies 12
Rabies - Therapeutics under Investigation by Universities/Institutes 14
Rabies - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Rabies - Products under Development by Companies 18
Rabies - Products under Investigation by Universities/Institutes 19
Rabies - Companies Involved in Therapeutics Development 20
Beijing Minhai Biotechnology Co., Ltd 20
Celltrion, Inc. 21
CureVac GmbH 22
Humabs BioMed SA 23
Kaketsuken K.K. 24
Kamada Ltd. 25
Medicago Inc. 26
Molecular Targeting Technologies, Inc. 27
NanoViricides, Inc. 28
Novavax, Inc. 29
PaxVax, Inc. 30
Prosetta Antiviral Inc. 31
Sanofi 32
Serum Institute of India Limited 33
Sinovac Biotech Ltd. 34
Trellis Bioscience, Inc. 35
VBI Vaccines Inc. 36
Zydus Cadila Healthcare Limited 37
Rabies - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
CTP-19 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CV-7201 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CV-8102 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ebola + rabies vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
human rabies vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KD-357 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies for Rabies - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibody for Rabies - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PAV-866 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
RabiCide-I - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rabies immune globulin (human) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
rabies vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
rabies vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rabies vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rabies vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rabies vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rabies vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
rabies vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rabies virus like particle vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Rabimabs - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SII RMab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SO-57 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
SOJB - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SYN-023 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
VerorabVax - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Rabies - Recent Pipeline Updates 75
Rabies - Dormant Projects 77
Rabies - Product Development Milestones 78
Featured News & Press Releases 78
Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies 78
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 79
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 79
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 80
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 80
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Rabies, H2 2015 10
Number of Products under Development for Rabies - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 20
Rabies - Pipeline by Celltrion, Inc., H2 2015 21
Rabies - Pipeline by CureVac GmbH, H2 2015 22
Rabies - Pipeline by Humabs BioMed SA, H2 2015 23
Rabies - Pipeline by Kaketsuken K.K., H2 2015 24
Rabies - Pipeline by Kamada Ltd., H2 2015 25
Rabies - Pipeline by Medicago Inc., H2 2015 26
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H2 2015 27
Rabies - Pipeline by NanoViricides, Inc., H2 2015 28
Rabies - Pipeline by Novavax, Inc., H2 2015 29
Rabies - Pipeline by PaxVax, Inc., H2 2015 30
Rabies - Pipeline by Prosetta Antiviral Inc., H2 2015 31
Rabies - Pipeline by Sanofi, H2 2015 32
Rabies - Pipeline by Serum Institute of India Limited, H2 2015 33
Rabies - Pipeline by Sinovac Biotech Ltd., H2 2015 34
Rabies - Pipeline by Trellis Bioscience, Inc., H2 2015 35
Rabies - Pipeline by VBI Vaccines Inc., H2 2015 36
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 37
Assessment by Monotherapy Products, H2 2015 38
Assessment by Combination Products, H2 2015 39
Number of Products by Stage and Target, H2 2015 40
Number of Products by Stage and Mechanism of Action, H2 2015 41
Number of Products by Stage and Route of Administration, H2 2015 43
Number of Products by Stage and Molecule Type, H2 2015 45
Rabies Therapeutics - Recent Pipeline Updates, H2 2015 75
Rabies - Dormant Projects, H2 2015 77